| 2.19 -0.01 (-0.45%) | 07-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Entasis Therapeutics Holdings Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to the discovery, development, and market introduction of novel antibacterial solutions. Their core mission in the United States is to address severe infections stemming from pathogens that exhibit multidrug resistance. A flagship program in their pipeline is sulbactam-durlobactam (SUL-DUR), an innovative intravenous antibiotic. This promising candidate is currently undergoing Phase III clinical evaluation for its effectiveness in treating pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company's developmental efforts extend to several other therapeutic agents. Zoliflodacin, a distinct orally administered molecule, is also progressing through Phase III clinical trials, aimed at uncomplicated gonorrhea. Furthermore, ETX0282CPDP, an oral drug, is being assessed in Phase I studies for its potential in treating urinary tract infections. From their NBP platform, ETX0462 is another drug candidate, presently in the pre-clinical stage, targeting a range of multidrug-resistant gram-negative infections. Entasis maintains key partnerships to advance its portfolio. A licensing and collaboration agreement is in place with Zai Lab (Shanghai) Co., Ltd. for the continued development of durlobactam and SUL-DUR. Additionally, they have a collaborative arrangement with the Global Antibiotic Research and Development Partnership for the development and subsequent commercialization of Zoliflodacin. Established in 2015, Entasis Therapeutics Holdings Inc. maintains its corporate headquarters in Waltham, Massachusetts, and functions as a subsidiary of Innoviva, Inc.
Mon, 11 Jul 2022
Innoviva Completes Acquisition of Entasis Therapeutics - businesswire.com
Tue, 19 Oct 2021
Entasis nears NDA filing for entrant in fight against tough Acinetobacter infections - BioWorld News
Sun, 23 Sep 2018
IPO News This Week: Survey Monkey Among 13 Offerings on Coming Week’s Calendar - 24/7 Wall St.
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|